This was a multicenter randomized phase III study. Random assignment was performed at the time of surgery in cases with residual tumor ≤0.25 cm. HIPEC with cisplatin (CDDP) 75 mg/m 2 for 60 minutes at ...

Background: Although immunotherapy has changed the treatment strategy for many cancers with great success, patients with microsatellite stable (MSS) and RAS-mutant metastatic colorectal cancer (mCRC) ...

Individual patient data from 20 randomized multicenter trials were collected. Eleven studies (4,773 patients) with sufficient data were analyzed to evaluate whether 9- or 12-month MRD-CR classified at ...

Our previous NECO phase II studies on high-grade osteosarcoma suggested that administering ifosfamide (IF; 16 g/m 2 [4g/m 2 once on day 1, then 2g/m 2 once on days 2-7] × six) to patients showing a ...

For the purpose of this paper, we define oncology rehabilitation as services provided by licensed medical providers (eg, physical or occupational therapists, physical medicine and rehabilitation ...

Colorectal cancer (CRC) is a prevalent and deadly disease worldwide. Around 1.9 million new cases and over 903,000 deaths were estimated in 2022. 1 In the United States, it has been projected that by ...

Early-stage, triple-negative breast cancer (TNBC) is the most challenging breast cancer (BC) subtype to treat, characterized by a higher histologic grade, resulting in relatively early and high ...

Enzalutamide (ENZA) and abiraterone acetate (AA) are the treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) in the United Kingdom. 1-4 In the real-world ...

Cancer treatment has evolved significantly, with a growing recognition that high-quality care extends beyond treating the disease alone. Multiple guidelines emphasize the need for comprehensive person ...

Risk of non-breast cancer–related mortality in breast cancer and dependence on disease characteristics, treatment, and survival duration. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

MCARH109 is a first-in-class G protein–coupled receptor, class C, group 5, member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple ...